https://www.selleckchem.com/pr....oducts/protac-tubuli
of patients treated with this combination, and side effects were manageable. Patients with advanced kidney cancer whose disease had worsened during treatment with atezolizumab or sunitinib began second-line treatment with atezolizumab + bevacizumab. Tumors shrank in more than one-quarter of patients treated with this combination, and side effects were manageable. Recent publications have reported an association between increased renal cancer-specific mortality (CSM) and reduced renal function "below safety limits," and
Like
Comment
Share
